Skip to main content
Erschienen in: Supportive Care in Cancer 11/2008

01.11.2008 | Review Article

A review of patient self-report tools for chemotherapy-induced nausea and vomiting

verfasst von: Sarah G. Brearley, Caroline V. Clements, Alex Molassiotis

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2008

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

The assessment of chemotherapy-induced nausea, vomiting and retching (CINVR) is important and to date no review has comprehensively assessed available patient self-report tools. The aim was to undertake a review of their utility, content and psychometric properties.

Materials and methods

One thousand three hundred and forty-seven citations were identified by electronic and hand searches resulting in 24 non-duplicate abstracts, 15 articles for analysis, and six articles, which fitted the inclusion criteria. E-mail investigations discovered a further scale, resulting in seven measures.

Results

The review highlighted the strengths and weaknesses of current tools. The multiple domains, phases and aspects of CINVR signify that the assessment tools varied markedly. The diverse requirements of research and clinicians also contribute to the variation. There was a notable disparity in the quality of scales and paucity in terms of their development and psychometric evaluation. We found that several self-assessment scales currently perceived as well-validated tools have problems in terms of their validity, reliability and appropriateness.

Conclusions

The constituents of a scale relevant for both clinical and research use were assessed and it was recommended that a modular tool focusing on two domains (nausea and vomiting); two phases (acute and delayed); measuring the aspects of occurrence, frequency, intensity alongside duration and functional interference; and antiemetic use and adverse events should be developed. Based on these recommendations, further research into an appropriate scale would minimise conceptual confusion, increase clinicians’ understanding and control of CINVR, decrease patient distress and could have equal utility in both a clinical and a research setting.
Literatur
1.
Zurück zum Zitat Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KC, Sullivan M, Takeda D (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KC, Sullivan M, Takeda D (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef
2.
Zurück zum Zitat Alves-Guerreiro J, Lowe-Strong AS, Walsh DM, Lopes BC, Costa R, Rosado R, Monforte E, Rolo T, Projecto J, Ferreira M (2003) Development of a Portuguese version of the Morrow Assessment of Nausea and Emesis (MANE) questionnaire: moving physical therapy forward [abstract]. 14th International World Confederation for Physical Therapy Congress Alves-Guerreiro J, Lowe-Strong AS, Walsh DM, Lopes BC, Costa R, Rosado R, Monforte E, Rolo T, Projecto J, Ferreira M (2003) Development of a Portuguese version of the Morrow Assessment of Nausea and Emesis (MANE) questionnaire: moving physical therapy forward [abstract]. 14th International World Confederation for Physical Therapy Congress
3.
Zurück zum Zitat Bergkvist K, Wengström Y (2006) Symptom experience during chemotherapy treatment—with focus on nausea and vomiting. Eur J Oncol Nurs 10:21–29PubMedCrossRef Bergkvist K, Wengström Y (2006) Symptom experience during chemotherapy treatment—with focus on nausea and vomiting. Eur J Oncol Nurs 10:21–29PubMedCrossRef
4.
Zurück zum Zitat Carnrike CLM Jr, Carey MP (1990) Assessing nausea and vomiting in adult chemotherapy patients: review and recommendations. Ann Behav Med 12:79–85CrossRef Carnrike CLM Jr, Carey MP (1990) Assessing nausea and vomiting in adult chemotherapy patients: review and recommendations. Ann Behav Med 12:79–85CrossRef
5.
Zurück zum Zitat Carnrike CLM, Brantley PJ, Bruce B, Faruqui S, Gresham FM, Buss RR, Cocke TB (1988) Test–restest reliability and concurrent validity of the Morrow Assessment of Nausea and Emesis (MANE) for the assessment of cancer chemotherapy- related nausea and vomiting. J Psychopathol Behav Assess 10:107–116CrossRef Carnrike CLM, Brantley PJ, Bruce B, Faruqui S, Gresham FM, Buss RR, Cocke TB (1988) Test–restest reliability and concurrent validity of the Morrow Assessment of Nausea and Emesis (MANE) for the assessment of cancer chemotherapy- related nausea and vomiting. J Psychopathol Behav Assess 10:107–116CrossRef
6.
Zurück zum Zitat Chou F-H, Avant KC, Kuo S-H, Cheng HF (2005) Assessing the psychometric and language equivalency of the Chinese versions of the index of nausea, vomiting and retching, and the prenatal self-evaluation questionnaire. Kaohsiung J Med Sci 21:314–321PubMedCrossRef Chou F-H, Avant KC, Kuo S-H, Cheng HF (2005) Assessing the psychometric and language equivalency of the Chinese versions of the index of nausea, vomiting and retching, and the prenatal self-evaluation questionnaire. Kaohsiung J Med Sci 21:314–321PubMedCrossRef
7.
Zurück zum Zitat Crucitt MA, Hyman W, Grote T, Tester W, Madajewicz S, Yee S, Wentz A, Griffin D, Parasuraman TV, Bryson J (1996) Efficacy and tolerability or oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphomide-based chemotherapy and maintenance of health-related quality of life. Clin Ther 18:778–788PubMedCrossRef Crucitt MA, Hyman W, Grote T, Tester W, Madajewicz S, Yee S, Wentz A, Griffin D, Parasuraman TV, Bryson J (1996) Efficacy and tolerability or oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphomide-based chemotherapy and maintenance of health-related quality of life. Clin Ther 18:778–788PubMedCrossRef
8.
Zurück zum Zitat Coates AS, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox R, Tattersall M (1983) On the receiving end: patient perception of the side effects of chemotherapy. Eur J Cancer Clin Oncol 19:203–208PubMedCrossRef Coates AS, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox R, Tattersall M (1983) On the receiving end: patient perception of the side effects of chemotherapy. Eur J Cancer Clin Oncol 19:203–208PubMedCrossRef
9.
Zurück zum Zitat de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, Verweij J (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055–1061PubMed de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, Verweij J (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055–1061PubMed
10.
Zurück zum Zitat Decker GM, DeMeyer ES, Kisko DL (2006) Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 4:35–41PubMed Decker GM, DeMeyer ES, Kisko DL (2006) Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 4:35–41PubMed
11.
Zurück zum Zitat DeGroot T, Einhorn L, Brames J, Roth BJ, Dreicer R, Nichols C, Bubalo J (2006) Multiple-day Palonosetron antiemetic regimen is safe and effective for preventing chemotherapy-induced nausea and vomiting in patients receiving 5-day Cisplatin for testicular cancer. Presented at Chicago Supportive Oncology Conference Sept 27–30 DeGroot T, Einhorn L, Brames J, Roth BJ, Dreicer R, Nichols C, Bubalo J (2006) Multiple-day Palonosetron antiemetic regimen is safe and effective for preventing chemotherapy-induced nausea and vomiting in patients receiving 5-day Cisplatin for testicular cancer. Presented at Chicago Supportive Oncology Conference Sept 27–30
12.
Zurück zum Zitat Dibble SL, Chapman J, Mack KA, Shih A (2000) Acupressure for nausea: results of a pilot study. Oncol Nurs Forum 27:41–47PubMed Dibble SL, Chapman J, Mack KA, Shih A (2000) Acupressure for nausea: results of a pilot study. Oncol Nurs Forum 27:41–47PubMed
13.
Zurück zum Zitat Dibble SL, Israel J, Nussey B, Casey K, Luce J (2003) Delayed chemotherapy-induced nausea in women treated for breast cancer. Oncol Nurs Forum 30:40–47CrossRef Dibble SL, Israel J, Nussey B, Casey K, Luce J (2003) Delayed chemotherapy-induced nausea in women treated for breast cancer. Oncol Nurs Forum 30:40–47CrossRef
14.
Zurück zum Zitat Farley PA, Dempsey CL, Shillington AA, Kulis-Robitaille C, Colgan K, Bernstein G (1997) Patients’ self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers. Am J Health-Syst Pharm 54:2478–2482PubMed Farley PA, Dempsey CL, Shillington AA, Kulis-Robitaille C, Colgan K, Bernstein G (1997) Patients’ self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers. Am J Health-Syst Pharm 54:2478–2482PubMed
15.
Zurück zum Zitat Fromme EK, Eilers KM, Mori M, Hsieh Y-C, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient- reported symptoms form the quality-of-life questionnaire C30. J Clin Oncol 22:3485–3490PubMedCrossRef Fromme EK, Eilers KM, Mori M, Hsieh Y-C, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient- reported symptoms form the quality-of-life questionnaire C30. J Clin Oncol 22:3485–3490PubMedCrossRef
16.
Zurück zum Zitat Fu MR, Rhodes V, Xu B (2002) The Chinese translation of the index of nausea, vomiting and retching. Cancer Nurs 25:134–140PubMedCrossRef Fu MR, Rhodes V, Xu B (2002) The Chinese translation of the index of nausea, vomiting and retching. Cancer Nurs 25:134–140PubMedCrossRef
17.
Zurück zum Zitat Glaus A, Knipping C, Morant R, Bohme C, Lebert B, Beldermann F, Glawogger B, Ortega PF, Husler A, Deuson R (2004) Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 12:708–715PubMedCrossRef Glaus A, Knipping C, Morant R, Bohme C, Lebert B, Beldermann F, Glawogger B, Ortega PF, Husler A, Deuson R (2004) Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 12:708–715PubMedCrossRef
18.
Zurück zum Zitat Gift AG, Jablonski A, Stommel M, Given WC (2004) Symptom clusters in elderly patients with lung cancer. Oncol Nurs Forum 31:203–209CrossRef Gift AG, Jablonski A, Stommel M, Given WC (2004) Symptom clusters in elderly patients with lung cancer. Oncol Nurs Forum 31:203–209CrossRef
19.
Zurück zum Zitat Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MHN (1996) On the receiving end v: patient perceptions of the side effects of chemotherapy in 1993. Ann Oncol 7:189–195PubMed Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MHN (1996) On the receiving end v: patient perceptions of the side effects of chemotherapy in 1993. Ann Oncol 7:189–195PubMed
20.
Zurück zum Zitat Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261–2268PubMedCrossRef Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261–2268PubMedCrossRef
21.
Zurück zum Zitat Hesketh PJ, Gralla RJ, du Bois A, Tonato M (1998) Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. Support Care Cancer 6:221–227PubMedCrossRef Hesketh PJ, Gralla RJ, du Bois A, Tonato M (1998) Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. Support Care Cancer 6:221–227PubMedCrossRef
22.
Zurück zum Zitat Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. J Clin Oncol 21:4112–4119PubMedCrossRef Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. J Clin Oncol 21:4112–4119PubMedCrossRef
23.
Zurück zum Zitat Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro AM, Gandara D, Lindley C (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103–109PubMed Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro AM, Gandara D, Lindley C (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103–109PubMed
24.
Zurück zum Zitat Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5 hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 1:2880–2886CrossRef Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5 hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 1:2880–2886CrossRef
25.
Zurück zum Zitat Hickock JT, Roscoe JA, Morrow GR, Stern RM, Yang B, Flynn PJ, Kirshner HE, Rosenbluth R (1999) Use of 5-HT3 receptor antagonists to prevent nausea and emesis caused by chemotherapy for patients with breast carcinoma in community practice settings. Cancer 86:64–71CrossRef Hickock JT, Roscoe JA, Morrow GR, Stern RM, Yang B, Flynn PJ, Kirshner HE, Rosenbluth R (1999) Use of 5-HT3 receptor antagonists to prevent nausea and emesis caused by chemotherapy for patients with breast carcinoma in community practice settings. Cancer 86:64–71CrossRef
26.
Zurück zum Zitat Honea N, Breant J, Beck SL (2007) Treatment related symptom cluster. Semin Oncol Nurs 23:142–151PubMedCrossRef Honea N, Breant J, Beck SL (2007) Treatment related symptom cluster. Semin Oncol Nurs 23:142–151PubMedCrossRef
27.
Zurück zum Zitat Huschka M, Burger K (2006) Does QOL provide the same information as toxicity data? Curr Probl Cancer 30:244–254PubMedCrossRef Huschka M, Burger K (2006) Does QOL provide the same information as toxicity data? Curr Probl Cancer 30:244–254PubMedCrossRef
28.
Zurück zum Zitat Kim YJ, Kim JY, Choi IR, Kim MW, Rhodes V (2000) The index of nausea, vomiting and retching (Korean Translation). Korean Acad Adult Nurs 12:278–285 Kim YJ, Kim JY, Choi IR, Kim MW, Rhodes V (2000) The index of nausea, vomiting and retching (Korean Translation). Korean Acad Adult Nurs 12:278–285
29.
Zurück zum Zitat Kobayashi K, Ishihara Y, Nukariya N, Niitani H, Furue H, Joint Research Group for Tropisetron Double-Blind Comparative Study (1999) Effects of an antiemetic drug (Tropisetron) on a quality of life during chemotherapy: use of a diary-type questionnaire and application of summary measures for assessment in a randomized, multicentre study. Respirology 4:229–238PubMedCrossRef Kobayashi K, Ishihara Y, Nukariya N, Niitani H, Furue H, Joint Research Group for Tropisetron Double-Blind Comparative Study (1999) Effects of an antiemetic drug (Tropisetron) on a quality of life during chemotherapy: use of a diary-type questionnaire and application of summary measures for assessment in a randomized, multicentre study. Respirology 4:229–238PubMedCrossRef
30.
Zurück zum Zitat Lebeau B, Depierre A, Giovanni M, Riviere A, Kaluzinski L, Votan B, Hédouin M, d’Allens H (1997) The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. Ann Oncol 8:887–892PubMedCrossRef Lebeau B, Depierre A, Giovanni M, Riviere A, Kaluzinski L, Votan B, Hédouin M, d’Allens H (1997) The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. Ann Oncol 8:887–892PubMedCrossRef
31.
Zurück zum Zitat Lindley CM, Hirsch JD, O’Neill CV, Transau MC, Gilbert CS, Osterhaus JT (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331–340PubMedCrossRef Lindley CM, Hirsch JD, O’Neill CV, Transau MC, Gilbert CS, Osterhaus JT (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331–340PubMedCrossRef
32.
Zurück zum Zitat Lo LH, Hayman LL (1999) Parents associated with children in measuring acute and delayed nausea and vomiting. Nurs Health Sci 1:155–161PubMedCrossRef Lo LH, Hayman LL (1999) Parents associated with children in measuring acute and delayed nausea and vomiting. Nurs Health Sci 1:155–161PubMedCrossRef
33.
Zurück zum Zitat Martin A, Pearson J, Cai B, Elmer M, Horgan K, Lindley CM (2000) Validation of a 5-day recall version of the Functional Living Index-Emesis (FLIE) quality of life questionnaire for chemotherapy-induced emesis. Qual Life Res 9:18 Martin A, Pearson J, Cai B, Elmer M, Horgan K, Lindley CM (2000) Validation of a 5-day recall version of the Functional Living Index-Emesis (FLIE) quality of life questionnaire for chemotherapy-induced emesis. Qual Life Res 9:18
34.
Zurück zum Zitat Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C (2003) Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 11:522–527PubMedCrossRef Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C (2003) Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 11:522–527PubMedCrossRef
35.
Zurück zum Zitat Martin AR, Carides AD, Pearson JD, Elmer M, Schmidt C, Cai B, Grunberg SM (2003) Functional relevance of antiemetic control—experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. Eur J Cancer 39:1395–1401PubMedCrossRef Martin AR, Carides AD, Pearson JD, Elmer M, Schmidt C, Cai B, Grunberg SM (2003) Functional relevance of antiemetic control—experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. Eur J Cancer 39:1395–1401PubMedCrossRef
36.
Zurück zum Zitat Martin CG, Rubenstein EB, Elting LS, Kim YJ, Osoba D (2003) Measuring chemotherapy-induced nausea and emesis. Psychometric properties of a quality of life questionnaire. Cancer 98:645–655PubMedCrossRef Martin CG, Rubenstein EB, Elting LS, Kim YJ, Osoba D (2003) Measuring chemotherapy-induced nausea and emesis. Psychometric properties of a quality of life questionnaire. Cancer 98:645–655PubMedCrossRef
37.
Zurück zum Zitat Miller M, Kearney N (2004) Chemotherapy-related nausea and vomiting- past reflections, present practice and future management. Eur J Cancer Care 13:71–81CrossRef Miller M, Kearney N (2004) Chemotherapy-related nausea and vomiting- past reflections, present practice and future management. Eur J Cancer Care 13:71–81CrossRef
38.
Zurück zum Zitat Molassiotis A, Börjeson S (2006) Nausea and vomiting. In: Kearney N, Richardson A (eds) Nursing patients with cancer: principles and practice. Edinburgh, Elsevier Churchill Livingstone, pp 415–43 Molassiotis A, Börjeson S (2006) Nausea and vomiting. In: Kearney N, Richardson A (eds) Nursing patients with cancer: principles and practice. Edinburgh, Elsevier Churchill Livingstone, pp 415–43
39.
Zurück zum Zitat Molassiotis A, Saunders M, Valle J, Wilson G, Lorigan P, Wardley A, Levine E, Cowan R, Loncaster J, Rittenberg C (2008) A prospective observational study of chemotherapy-induced nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 16:201–208 Molassiotis A, Saunders M, Valle J, Wilson G, Lorigan P, Wardley A, Levine E, Cowan R, Loncaster J, Rittenberg C (2008) A prospective observational study of chemotherapy-induced nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 16:201–208
40.
Zurück zum Zitat Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC Antiemesis Tool (MAT). J Pain Symptom Manage 34:148–159PubMedCrossRef Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC Antiemesis Tool (MAT). J Pain Symptom Manage 34:148–159PubMedCrossRef
41.
Zurück zum Zitat Molassiotis A, Helin AM, Dabbour R, Hummerston S (2007) The effects of P6 acupressure in the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients. Comp Ther Med 15:3–7CrossRef Molassiotis A, Helin AM, Dabbour R, Hummerston S (2007) The effects of P6 acupressure in the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients. Comp Ther Med 15:3–7CrossRef
42.
Zurück zum Zitat Molassiotis A, Yung HP, Yam BM, Chan FY, Mok TS (2002) The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. A randomised controlled trial. Support Care Cancer 10:237–246PubMedCrossRef Molassiotis A, Yung HP, Yam BM, Chan FY, Mok TS (2002) The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. A randomised controlled trial. Support Care Cancer 10:237–246PubMedCrossRef
43.
Zurück zum Zitat Morrow G (1984) Methodology in behavioural and psychosocial cancer research. The assessment nausea and vomiting. Past problems, current issues, and suggestions for future research. Cancer 53(Suppl):2267–2278PubMed Morrow G (1984) Methodology in behavioural and psychosocial cancer research. The assessment nausea and vomiting. Past problems, current issues, and suggestions for future research. Cancer 53(Suppl):2267–2278PubMed
44.
Zurück zum Zitat Morrow G (1992) A patient report measure for the quantification of chemotherapy induced nausea and emesis: psychometric properties of the Morrow assessment of nausea and emesis (MANE). Br J Cancer 66(Suppl XIX):S72–S74 Morrow G (1992) A patient report measure for the quantification of chemotherapy induced nausea and emesis: psychometric properties of the Morrow assessment of nausea and emesis (MANE). Br J Cancer 66(Suppl XIX):S72–S74
45.
Zurück zum Zitat Mullin SM, Fletcher DM, Tyler LS (1998) Mail-in questionnaire for monitoring nausea and vomiting in oncology outpatients. Am J Health-Syst Pharm 55:1903–1906PubMed Mullin SM, Fletcher DM, Tyler LS (1998) Mail-in questionnaire for monitoring nausea and vomiting in oncology outpatients. Am J Health-Syst Pharm 55:1903–1906PubMed
46.
Zurück zum Zitat Olver IN, Matthews JP, Bishop JF, Smith RA (1994) The roles of patient and observer assessments in anti-emetic trials. Eur J Cancer 30:1223–1227CrossRef Olver IN, Matthews JP, Bishop JF, Smith RA (1994) The roles of patient and observer assessments in anti-emetic trials. Eur J Cancer 30:1223–1227CrossRef
47.
Zurück zum Zitat Osoba D (1994) Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 12:608–616PubMed Osoba D (1994) Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 12:608–616PubMed
48.
Zurück zum Zitat Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 5:307–313PubMedCrossRef Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 5:307–313PubMedCrossRef
49.
Zurück zum Zitat Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 15:116–123PubMed Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 15:116–123PubMed
50.
Zurück zum Zitat Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Guoguang JM, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: Results form a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090–3097PubMedCrossRef Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Guoguang JM, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: Results form a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090–3097PubMedCrossRef
51.
Zurück zum Zitat Presant CA (1984) Quality of life in cancer patients. Who measures what? Am J Clin Oncol 7:571–573PubMedCrossRef Presant CA (1984) Quality of life in cancer patients. Who measures what? Am J Clin Oncol 7:571–573PubMedCrossRef
52.
Zurück zum Zitat Rhodes VA, Watson PM, Johnson MH (1984) Development of reliable and valid measures of nausea and vomiting. Cancer Nurs 7:33–41PubMedCrossRef Rhodes VA, Watson PM, Johnson MH (1984) Development of reliable and valid measures of nausea and vomiting. Cancer Nurs 7:33–41PubMedCrossRef
53.
Zurück zum Zitat Rhodes VA, McDaniel RW (1997) Measuring nausea, vomiting and retching. In: Frank-Stromborg M, Olsen SJ (eds) Instruments for clinical health-care research,. 2nd edn. Jones & Bartlett, Boston, pp 509–518 Rhodes VA, McDaniel RW (1997) Measuring nausea, vomiting and retching. In: Frank-Stromborg M, Olsen SJ (eds) Instruments for clinical health-care research,. 2nd edn. Jones & Bartlett, Boston, pp 509–518
54.
Zurück zum Zitat Rhodes VA, McDaniel RW (1999) The index of nausea, vomiting, and retching: a new format of the lndex of nausea and vomiting. Oncol Nurs Forum 26:889–894PubMed Rhodes VA, McDaniel RW (1999) The index of nausea, vomiting, and retching: a new format of the lndex of nausea and vomiting. Oncol Nurs Forum 26:889–894PubMed
55.
Zurück zum Zitat Roscoe JA, Morrow GR, Hickok JT, Stern RM (2000) Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage 20:113–121PubMedCrossRef Roscoe JA, Morrow GR, Hickok JT, Stern RM (2000) Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage 20:113–121PubMedCrossRef
56.
Zurück zum Zitat Sarna L (1998) Effectiveness of structured nursing assessment of symptom distress in advanced lung cancer. Oncol Nurs Forum 25:1041–1048PubMed Sarna L (1998) Effectiveness of structured nursing assessment of symptom distress in advanced lung cancer. Oncol Nurs Forum 25:1041–1048PubMed
57.
Zurück zum Zitat Satou A, Yamazaki T, Nukariya N, Nakamachi M, Shimada K, Matsukawa M, Kurihara M (2002) Development of a Japanese version of the FLIE. Japanese Journal of Cancer and Chemotherapy 28:281–291 Satou A, Yamazaki T, Nukariya N, Nakamachi M, Shimada K, Matsukawa M, Kurihara M (2002) Development of a Japanese version of the FLIE. Japanese Journal of Cancer and Chemotherapy 28:281–291
58.
Zurück zum Zitat Schipper H, Clinch J, McMurray A, Levitt M (1984) Measuring the quality of life of cancer patients: the functional living index-cancer: development and validation. J Clin Oncol 2:472–483PubMed Schipper H, Clinch J, McMurray A, Levitt M (1984) Measuring the quality of life of cancer patients: the functional living index-cancer: development and validation. J Clin Oncol 2:472–483PubMed
59.
Zurück zum Zitat Schwartzberg L (2006) Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol 4:3–8PubMed Schwartzberg L (2006) Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol 4:3–8PubMed
60.
Zurück zum Zitat Smith HS (2005) A receptor-based paradigm of nausea and vomiting. J Cancer Pain Symptom Pall 1:11–23CrossRef Smith HS (2005) A receptor-based paradigm of nausea and vomiting. J Cancer Pain Symptom Pall 1:11–23CrossRef
61.
Zurück zum Zitat Streiner DL (1993) A checklist for evaluating the usefulness of rating scales. Can J Psychiatry 38:140–148PubMed Streiner DL (1993) A checklist for evaluating the usefulness of rating scales. Can J Psychiatry 38:140–148PubMed
62.
Zurück zum Zitat Streiner DL, Norman GR (1995) Health measurement scales: a practical guide to their development and use, 2nd edn. Oxford University Press, New York Streiner DL, Norman GR (1995) Health measurement scales: a practical guide to their development and use, 2nd edn. Oxford University Press, New York
63.
Zurück zum Zitat Sykes AJ, Kiltie AE, Stewart AL (1997) Ondasetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. Support Care Cancer 5:500–503PubMedCrossRef Sykes AJ, Kiltie AE, Stewart AL (1997) Ondasetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. Support Care Cancer 5:500–503PubMedCrossRef
Metadaten
Titel
A review of patient self-report tools for chemotherapy-induced nausea and vomiting
verfasst von
Sarah G. Brearley
Caroline V. Clements
Alex Molassiotis
Publikationsdatum
01.11.2008
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 11/2008
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-008-0428-y

Weitere Artikel der Ausgabe 11/2008

Supportive Care in Cancer 11/2008 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.